AU2008328584A1 - Novel polypeptides having endolysin activity and uses thereof - Google Patents

Novel polypeptides having endolysin activity and uses thereof Download PDF

Info

Publication number
AU2008328584A1
AU2008328584A1 AU2008328584A AU2008328584A AU2008328584A1 AU 2008328584 A1 AU2008328584 A1 AU 2008328584A1 AU 2008328584 A AU2008328584 A AU 2008328584A AU 2008328584 A AU2008328584 A AU 2008328584A AU 2008328584 A1 AU2008328584 A1 AU 2008328584A1
Authority
AU
Australia
Prior art keywords
cells
polypeptide
bacteriophage
clostridium difficile
endolysin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008328584A
Other languages
English (en)
Inventor
Michael Gasson
Melinda Mayer
Arjan Narbad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Plant Bioscience Ltd
Original Assignee
Plant Bioscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plant Bioscience Ltd filed Critical Plant Bioscience Ltd
Publication of AU2008328584A1 publication Critical patent/AU2008328584A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/06—Lysis of microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G01N2333/98—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2008328584A 2007-11-26 2008-11-24 Novel polypeptides having endolysin activity and uses thereof Abandoned AU2008328584A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99656307P 2007-11-26 2007-11-26
US60/996,563 2007-11-26
PCT/GB2008/003923 WO2009068858A1 (en) 2007-11-26 2008-11-24 Novel polypeptides having endolysin activity and uses thereof

Publications (1)

Publication Number Publication Date
AU2008328584A1 true AU2008328584A1 (en) 2009-06-04

Family

ID=40303496

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008328584A Abandoned AU2008328584A1 (en) 2007-11-26 2008-11-24 Novel polypeptides having endolysin activity and uses thereof

Country Status (6)

Country Link
US (2) US20100310522A1 (enExample)
EP (1) EP2225263A1 (enExample)
JP (1) JP2011504366A (enExample)
AU (1) AU2008328584A1 (enExample)
CA (1) CA2706600A1 (enExample)
WO (1) WO2009068858A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0815484D0 (en) 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
GB0908949D0 (en) * 2009-05-26 2009-07-01 Plant Bioscience Ltd Novel polypeptides having endolysin activity and uses thereof
EP2446028B1 (en) 2009-06-26 2018-04-04 Lysando Aktiengesellschaft Antimicrobial agents
PL2445515T3 (pl) 2009-06-26 2016-10-31 Środki przeciwdrobnoustrojowe
CN103857410A (zh) 2011-04-21 2014-06-11 洛克菲勒大学 用于革兰氏阳性菌检测和治疗的链球菌属细菌噬菌体溶素
KR101177358B1 (ko) 2011-11-10 2012-08-27 서울대학교산학협력단 펩티다아제 활성이 있는 엔돌라이신 ＬｙｓＢ４, 이를 포함하는 식품 및 사료 조성물
GB201215184D0 (en) * 2012-08-24 2012-10-10 Univ Leicester Therapeutic virus
US9493518B2 (en) * 2013-03-14 2016-11-15 National Health Research Institutes Compositions and methods for treating clostridium difficile-associated diseases
WO2017044989A1 (en) * 2015-09-13 2017-03-16 The Rockefeller University Clostridium difficile BACTERIOPHAGE LYSINS FOR DETECTION AND TREATMENT OF Clostridium difficile BACTERIA INFECTION
KR101880929B1 (ko) 2016-06-30 2018-08-16 경희대학교 산학협력단 미생물 검출용 융합 단백질, 및 이의 제조방법
EP3372091A1 (en) * 2017-03-07 2018-09-12 Nomad Bioscience GmbH Method of reducing contamination of an object with clostridium
US20220112251A1 (en) * 2018-12-24 2022-04-14 University Of South Florida Engineered lysin-human defensin protein
US20220315908A1 (en) * 2019-05-08 2022-10-06 Phagomed Biopharma Gmbh Novel gardnerella endolysins and uses thereof
WO2022182830A1 (en) * 2021-02-25 2022-09-01 Trustees Of Dartmouth College Thermostable clostridium difficile lysins
AU2023304968A1 (en) * 2022-07-05 2025-01-16 Aushealth Corporate Pty Ltd Method of production of modified phage and method of treatment using same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1203333B (it) * 1987-02-16 1989-02-15 Endura Spa Impiego di derivati del metilendiossibenzene con funzione sinergizzante in composizioni per uso insetticida
GB2255561B (en) * 1991-04-20 1995-06-21 Agricultural & Food Res Lysins from bacteriophages
WO1995003035A1 (en) * 1993-07-23 1995-02-02 Massachusetts Institute Of Technology Polymerized liposomes with enhanced stability for oral delivery
US6225290B1 (en) * 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation
ID29150A (id) * 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
GB0202556D0 (en) * 2002-02-04 2002-03-20 Danisco Novel Protein
SE0201659D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation

Also Published As

Publication number Publication date
EP2225263A1 (en) 2010-09-08
US20160045578A1 (en) 2016-02-18
US20100310522A1 (en) 2010-12-09
JP2011504366A (ja) 2011-02-10
WO2009068858A1 (en) 2009-06-04
CA2706600A1 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
US20160045578A1 (en) Novel Polypeptides Having Endolysin Activity and Uses Thereof
KR102084388B1 (ko) 박테리오파지 리신을 이용한 생물막의 예방, 붕괴 및 치료
AU2009266982B2 (en) A chimeric bacteriophage lysin with activity against staphylococci bacteria
US20100004321A1 (en) Recombinant Staphylococcal Phage Lysin as an Antibacterial Agent
US7371375B2 (en) Protein
KR20230113404A (ko) 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의병용물
US20160040148A1 (en) Novel Polypeptides Having Endolysin Activity and Uses Thereof
US9752136B2 (en) Polypeptides having endolysin activity and uses thereof
Heselpoth et al. Enzybiotics: endolysins and bacteriocins
US7838255B2 (en) Nucleic acids and polypeptides of C1 bacteriophage and uses thereof
EP2143729A1 (en) New enzymatic active enzyme against Clostridium
Heselpoth et al. Enzybiotics: endolysins and bacteriocins
KR102534221B1 (ko) 신규한 폴리펩타이드 및 이를 포함하는 그람음성균에 대한 항생제
US20070254321A1 (en) Lytic Enzymes and Spore Surface Antigen for Detection and Treatment of Bacillus Anthracis Bacteria and Spores
KR101595976B1 (ko) 황색포도알균에 특이적 항균 활성을 가지는 리신 융합 단백질 및 이의 용도
Horgan et al. The use of recombinant phage lysins for the control of bacterial pathogens
장윤지 Characterization and Application of Bacteriophages and Endolysins as Biocontrol Agents to Combat Staphylococcus aureus
Horgan et al. he Use of Recombinant Phage Lysins for the Control of Bacterial Pathogens
Wang et al. Identification and characterization of the two-component cell lysis cassette encoded by temperate bacteriophage uPYB5 of Lactobacillus fermentum

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted